ReviewMolecular pharmaceutics2012
Exploiting dendrimer multivalency to combat emerging and re-emerging infectious diseases.
Review in Molecular pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Advances in Dendrimer-Based Anti-Infective Systems: In Vivo Insights and Perspectives.Pharmaceutics · 2026Review
- Calprotectin as a Biomarker for Infectious Diseases: A Comparative Review with Conventional Inflammatory Markers.International journal of molecular sciences · 2025Review
- A Comprehensive Review of Molecular Mechanisms Leading to the Emergence of Multidrug Resistance in Bacteria.Indian journal of microbiology · 2025Review
- Nanomedicines as a cutting-edge solution to combat antimicrobial resistance.RSC advances · 2024Review
- Targeting the phosphatidylglycerol lipid: An amphiphilic dendrimer as a promising antibacterial candidate.Science advances · 2024Article
- Metallo-Glycodendrimeric Materials against EnterotoxigenicMicroorganisms · 2024Article
- Vancomycin-Polyguanidino Dendrimer Conjugates Inhibit Growth of Antibiotic-Resistant Gram-Positive and Gram-Negative Bacteria and Eradicate Biofilm-AssociatedACS infectious diseases · 2024Article
- Powering mesoporous silica nanoparticles into bioactive nanoplatforms for antibacterial therapies: strategies and challenges.Journal of nanobiotechnology · 2023Review
- Preparation and Functionalization of Polymers with Antibacterial Properties-Review of the Recent Developments.Materials (Basel, Switzerland) · 2023Review
- Aza-Michael promoted glycoconjugation of PETIM dendrimers and selectivity in mycobacterial growth inhibitions.RSC advances · 2023Article
- Advanced bioactive nanomaterials for diagnosis and treatment of major chronic diseases.Frontiers in molecular biosciences · 2023Review
- Prevention and Eradication of Biofilm by Dendrimers: A Possibility Still Little Explored.Pharmaceutics · 2022Review
- The Antibacterial Effect of PEGylated Carbosilane Dendrimers onInternational journal of molecular sciences · 2022Article
- Editorial: The Pivotal Role of Oral Microbiota Dysbiosis and Microbiota-Host Interactions in Diseases.Frontiers in cellular and infection microbiology · 2022Article
- NMR Hydrophilic Metabolomic Analysis of Bacterial Resistance Pathways Using Multivalent Antimicrobials with Challenged and Unchallenged Wild Type and Mutated Gram-Positive Bacteria.International journal of molecular sciences · 2021Article
- Functionalized Dendrimer Platforms as a New Forefront Arsenal Targeting SARS-CoV-2: An Opportunity.Pharmaceutics · 2021Review
- Molecular Umbrella as a Nanocarrier for Antifungals.Molecules (Basel, Switzerland) · 2021Article
- Developments in Treatment Methodologies Using Dendrimers for Infectious Diseases.Molecules (Basel, Switzerland) · 2021Review
- Synthesis, Enzymatic Degradation, and Polymer-Miscibility Evaluation of Nonionic Antimicrobial Hyperbranched Polyesters with Indole or Isatin Functionalities.Biomacromolecules · 2021Article
- Gold(III) Aryl Complexes as Reagents for Constructing Hybrid Peptide-Based Assemblies via CysteineInorganic chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The emergence and re-emergence of bacterial strains that are resistant to current antibiotics reveal the clinical need for new agents that possess broad-spectrum antibacterial activity. Furthermore, bacteriophobic coatings that repel bacteria are important for medical devices, as the lifetime, reliability, and performance of implant devices are hindered by bacterial adhesion and infection. Dendrimers, a specific class of monodisperse macromolecules, have recently shown potential to function as both antibacterial agents and antimicrobial surface coatings. This review discusses the limitations with currently used antibacterial agents and describes how various classes of dendrimers, including glycodendrimers, cationic dendrimers, anionic dendrimers, and peptide dendrimers, have the potential to improve upon or replace certain antibiotics. Furthermore, the unexplored areas in this field of research will be mentioned to present opportunities for additional studies regarding the use of dendrimers as antimicrobial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.